Furthermore, in subgroup analyses stratified by diabetes status, associations of TET2 CHIP with adverse outcomes were generally stronger in women with diabetes (eg, for CHD: aHR: 2.03 [95% CI: 1.19-3.45]; P = 0.009 in those with diabetes; aHR: 1.22 [95% CI: 0.90-1.65]; P = 0.21 in those without diabetes), although corresponding interactions did not reach statistical significance ( Supplemental Figure 11 ).
1
—
—